Metformin: When Should We Fear Lactic Acidosis?

Area of Science:

• Pharmacology
• Nephrology
• Endocrinology

Background:

• Metformin, a biguanide, is a globally prevalent medication for diabetes mellitus.
• Despite extensive use and documented benefits beyond diabetes, concerns persist regarding lactic acidosis risk.
• Its chemical similarity to other biguanides fuels apprehension about potential adverse effects, particularly renal complications.

Purpose of the Study:

• To investigate the relationship between metformin use and the occurrence of renal damage.
• To evaluate the incidence and risk factors associated with metformin-associated lactic acidosis.
• To clarify the safety profile of metformin concerning lactic acidosis and renal health.

Main Methods:

• Literature review of studies on metformin, diabetes mellitus, and lactic acidosis.
• Analysis of clinical data and case reports concerning metformin-associated adverse events.
• Pharmacological assessment of metformin's mechanism of action and renal excretion pathways.

Main Results:

• Metformin-associated lactic acidosis is an infrequent complication.
• The risk of lactic acidosis is significantly elevated in patients with pre-existing renal impairment or contraindications.
• Careful patient selection and monitoring can mitigate the risks associated with metformin therapy.

Conclusions:

• Metformin is generally safe and effective for diabetes treatment when used appropriately.
• The benefits of metformin outweigh the rare risks of lactic acidosis in properly selected patients.
• Adherence to prescribing guidelines and vigilant monitoring are crucial for maximizing metformin's therapeutic advantages while minimizing potential harm.